economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

Biocytogen

Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment OG_NewsReleaseCompanyLogo_93085.jpg

Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment

creativebharatgroup@gmail.com January 10, 2025
Beijing, China & Prague, Czech Republic:   Biocytogen (HKEX: 02315), a global biotech...
Read More Read more about Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors OG_NewsReleaseCompanyLogo_93053.jpg

Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors

creativebharatgroup@gmail.com January 8, 2025
Beijing, China & Taipei, Taiwan & Alameda, Calif., United States:    Collaboration initiates...
Read More Read more about Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise OG_NewsReleaseCompanyLogo_92393.jpg

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

creativebharatgroup@gmail.com November 11, 2024
Beijing, China & South San Francisco, Calif., United States:   IDEAYA has...
Read More Read more about Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise